BR112021022831A2 - Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1 - Google Patents
Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1Info
- Publication number
- BR112021022831A2 BR112021022831A2 BR112021022831A BR112021022831A BR112021022831A2 BR 112021022831 A2 BR112021022831 A2 BR 112021022831A2 BR 112021022831 A BR112021022831 A BR 112021022831A BR 112021022831 A BR112021022831 A BR 112021022831A BR 112021022831 A2 BR112021022831 A2 BR 112021022831A2
- Authority
- BR
- Brazil
- Prior art keywords
- lag
- administration
- bispecific antibody
- dosage regimens
- regimens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906807.1A GB201906807D0 (en) | 2019-05-14 | 2019-05-14 | Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody |
| GB201914040A GB201914040D0 (en) | 2019-09-30 | 2019-09-30 | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody |
| GBGB2000318.2A GB202000318D0 (en) | 2020-01-09 | 2020-01-09 | Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody |
| PCT/EP2020/063529 WO2020229626A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022831A2 true BR112021022831A2 (pt) | 2022-01-18 |
Family
ID=70775359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022831A BR112021022831A2 (pt) | 2019-05-14 | 2020-05-14 | Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1 |
Country Status (12)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| CN118165116A (zh) * | 2021-03-31 | 2024-06-11 | 美勒斯公司 | 新型多特异性抗体 |
| US20240101718A1 (en) * | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
| GB202304278D0 (en) | 2023-03-23 | 2023-05-10 | F Star Therapeutics Ltd | Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7085709B2 (ja) | 2016-06-20 | 2022-06-17 | エフ-スター セラピューティクス リミテッド | Pd-l1及びlag-3に結合する結合分子 |
| JP2020522495A (ja) * | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| WO2018222718A1 (en) * | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
-
2020
- 2020-05-14 KR KR1020217040782A patent/KR20220008316A/ko not_active Ceased
- 2020-05-14 BR BR112021022831A patent/BR112021022831A2/pt not_active IP Right Cessation
- 2020-05-14 MX MX2021013943A patent/MX2021013943A/es unknown
- 2020-05-14 CA CA3139003A patent/CA3139003A1/en active Pending
- 2020-05-14 JP JP2021566974A patent/JP2022533578A/ja active Pending
- 2020-05-14 CN CN202080051441.8A patent/CN114206939A/zh active Pending
- 2020-05-14 AU AU2020275209A patent/AU2020275209A1/en not_active Abandoned
- 2020-05-14 EP EP20726768.3A patent/EP3969477A1/en not_active Withdrawn
- 2020-05-14 WO PCT/EP2020/063529 patent/WO2020229626A1/en not_active Ceased
- 2020-05-14 US US17/610,873 patent/US20220275092A1/en not_active Abandoned
- 2020-05-14 SG SG11202112136RA patent/SG11202112136RA/en unknown
-
2021
- 2021-11-10 IL IL287979A patent/IL287979A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112136RA (en) | 2021-11-29 |
| WO2020229626A1 (en) | 2020-11-19 |
| US20220275092A1 (en) | 2022-09-01 |
| JP2022533578A (ja) | 2022-07-25 |
| IL287979A (en) | 2022-01-01 |
| EP3969477A1 (en) | 2022-03-23 |
| KR20220008316A (ko) | 2022-01-20 |
| CN114206939A (zh) | 2022-03-18 |
| CA3139003A1 (en) | 2020-11-19 |
| AU2020275209A1 (en) | 2021-12-23 |
| MX2021013943A (es) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013943A (es) | Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. | |
| BR112021008582A8 (pt) | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer | |
| BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
| BR112022012437A2 (pt) | Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo | |
| Nair et al. | Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
| BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| CL2016002585A1 (es) | Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373) | |
| PE20180131A1 (es) | Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cancer | |
| BR112018075371A2 (pt) | usos terapêuticos de um inibidor de c-raf | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| CR20250348A (es) | ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-463) | |
| BR112019010903A2 (pt) | estrutura de cristal de gremlin-1 e anticorpo inibidor | |
| Morris et al. | Results of a 5-week schedule of modern total skin electron beam radiation therapy | |
| BR112021008679A2 (pt) | Métodos para tratar câncer, e composição farmacêutica | |
| BR112021006223A2 (pt) | regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi) | |
| Stamelos et al. | Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells | |
| Daver et al. | Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options | |
| BR112022021447A2 (pt) | Moléculas de ligação para o tratamento de câncer | |
| BR112022022900A2 (pt) | Método de tratamento de um câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2880 DE 17-03-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |